Anuh Pharma

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE489G01022
NSEID: ANUHPHR
BSEID: 506260

INR

82.55

3.39 (4.28%)

BSENSE

Dec 05

BSE+NSE Vol: 1.77 lacs

{
  "main_header": {
    "sid": 905552,
    "name": "Anuh Pharma",
    "stock_name": "Anuh Pharma",
    "full_name": "Anuh Pharma Ltd",
    "name_url": "stocks-analysis/anuh-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "82.55",
    "chg": 3.39,
    "chgp": "4.28%",
    "dir": 1,
    "prev_price": "79.16",
    "mcapval": "797.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 506260,
    "symbol": "ANUHPHR",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE489G01022",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "1.77 lacs",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/anuh-pharma-905552-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Why is Anuh Pharma falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-anuh-pharma-fallingrising-3749601",
        "imagepath": "",
        "date": "2025-12-06 01:31:09",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Short-Term Gains Outpace Benchmark</strong></p>\n<p>In the immediate term, Anuh Pharma’s stock has outperformed the broader market and its sector peers. Over the past week, the stock surged by 7.18%, significantly eclipsing the Sensex’s marginal gain of 0.01%. This recent momentum is further underscored by the stock’s intraday high of ₹83.25, representing a 5.17% increase on the day. Such performance indicates renewed investor interest and buying activity, possibly driven by short-term catalysts or market sentiment favouring the pharmaceutical sector.</p>\n<p>Despite this positive momentum, the stock’s monthly performance remains subdued, with a decline of 5.85% compared to the Sensex’s 2.70% gain. This suggests that while recent trading sessions have been favourable, the stock has faced headw..."
      },
      {
        "title": "Anuh Pharma Faces Intense Selling Pressure Amid Prolonged Downtrend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/anuh-pharma-faces-severe-selling-pressure-amidst-lower-circuit-lockdown-3748316",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AnuhPharma_only_sellers_3748316.png",
        "date": "2025-12-05 09:51:02",
        "description": "Anuh Pharma Ltd is currently experiencing extreme selling pressure, with the stock registering only sell orders and no buyers in the queue. This distress selling signals a challenging phase for the pharmaceutical and biotechnology company, as it continues to face a prolonged downtrend against broader market gains."
      },
      {
        "title": "Is Anuh Pharma technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-anuh-pharma-technically-bullish-or-bearish-3743024",
        "imagepath": "",
        "date": "2025-12-03 08:42:46",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Technical Trend Shift and Moving Averages</strong></p>\n<p>As of 2 December 2025, Anuh Pharma’s technical trend has shifted from mildly bearish to outright bearish. This change reflects a deterioration in the stock’s momentum and signals increased selling pressure. The daily moving averages reinforce this view, showing a bearish alignment that typically indicates downward price movement in the near term. Moving averages are a key tool for traders to identify trend direction, and a bearish stance here suggests that the stock is struggling to maintain upward momentum.</p>\n<p><strong>MACD and Momentum Indicators</strong></p>\n<p>The Moving Average Convergence Divergence (MACD) indicator, a popular momentum oscillator, presents a mixed but predominantly negative picture. On a weekly basis, the MAC..."
      },
      {
        "title": "Anuh Pharma Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/anuh-pharma-technical-momentum-shifts-amid-bearish-signals-3742938",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AnuhPharma_technicaldot_3742938.png",
        "date": "2025-12-03 08:07:05",
        "description": "Anuh Pharma, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflecting a complex interplay of bearish and mildly bullish signals across various timeframes. Recent evaluation adjustments highlight a transition in the stock’s technical trend, prompting a closer examination of its price action and indicator readings amid broader market conditions."
      },
      {
        "title": "Anuh Pharma’s Market Assessment Shifts Amid Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/anuh-pharma-stock-rating-upgraded-to-sell-amid-mixed-technical-and-financial-signals-3740721",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AnuhPharma_mojoScore_3740721.png",
        "date": "2025-12-02 08:48:13",
        "description": "Anuh Pharma has experienced a revision in its market evaluation following a complex interplay of financial performance, valuation metrics, and technical indicators. Despite recent quarterly setbacks and underperformance relative to broader indices, subtle shifts in technical trends and promoter activity have influenced the company’s overall market assessment."
      },
      {
        "title": "Anuh Pharma Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/anuh-pharma-technical-momentum-shifts-amid-mixed-market-signals-3740257",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/AnuhPharma_technicaldot_3740257.png",
        "date": "2025-12-02 08:09:33",
        "description": "Anuh Pharma, a player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflecting a complex interplay of market forces. Recent price movements and technical indicators reveal a nuanced picture of the stock’s near-term trajectory, with mixed signals from key momentum and trend-following tools."
      },
      {
        "title": "How has been the historical performance of Anuh Pharma?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-anuh-pharma-3739322",
        "imagepath": "",
        "date": "2025-12-01 23:24:48",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue and Profitability Trends</strong></p>\n<p>Over the seven-year period ending March 2025, Anuh Pharma’s net sales have shown a robust upward trend, rising from ₹320.66 crores in 2019 to ₹661.51 crores in 2025. This represents more than a doubling of sales, reflecting the company’s expanding market presence and operational scale. The total operating income mirrors this growth, with no other operating income reported, indicating that core business activities are the primary revenue drivers.</p>\n<p>Despite fluctuations in raw material costs and other expenses, the company has maintained a positive operating profit margin. Operating profit before other income (PBDIT excl OI) increased from ₹29.53 crores in 2019 to ₹60.90 crores in 2025, although the margin percentage saw some variability, p..."
      },
      {
        "title": "Anuh Pharma Faces Significant Selling Pressure with 27.42% Year-to-Date Loss Amid Poor Performance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/anuh-pharma-faces-significant-selling-pressure-with-2742-year-to-date-loss-amid-poor-performance-3700913",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AnuhPharma_only_sellers_3700913.png",
        "date": "2025-11-14 09:51:01",
        "description": "Anuh Pharma Ltd is experiencing notable selling pressure, continuing a trend of losses. The stock has declined significantly over various time frames, contrasting sharply with the Sensex's performance. Factors contributing to this trend include underperformance relative to its sector and trading below key moving averages."
      },
      {
        "title": "How has been the historical performance of Anuh Pharma?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-anuh-pharma-3694135",
        "imagepath": "",
        "date": "2025-11-12 23:21:44",
        "description": "Answer:\nThe historical performance of Anuh Pharma shows a steady growth in net sales and profitability over the years, with some fluctuations in costs and margins.\n\nBreakdown:\nAnuh Pharma's net sales increased from 486.65 Cr in Mar'22 to 661.51 Cr in Mar'25, reflecting a consistent upward trend. Total operating income followed a similar trajectory, rising from 486.65 Cr in Mar'22 to 661.51 Cr in Mar'25. However, the raw material costs peaked at 489.73 Cr in Mar'24 before declining to 463.28 Cr in Mar'25. Operating profit (PBDIT) saw a decline from 87.24 Cr in Mar'24 to 70.36 Cr in Mar'25, while profit before tax also decreased from 78.31 Cr to 61.01 Cr in the same period. Profit after tax mirrored this trend, dropping from 60.06 Cr in Mar'24 to 47.35 Cr in Mar'25. The company's total assets grew from 347.17 Cr in Mar'22 to 504.55 Cr in Mar'25, and total liabilities increased from 347.17 Cr to 504.55 Cr duri..."
      }
    ],
    "total": 5104,
    "sid": "905552",
    "stock_news_url": "https://www.marketsmojo.com/news/anuh-pharma-905552"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
      "datetime": "17-Nov-2025",
      "details": "Investor Presentation for Q2 FY 2025-26",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "09-Nov-2025",
      "details": "Newspaper publication of the Un-Audited financial results for the Quarter and Half year ended 30th September 2025 published in the Financial Express in English Language and Mumbai Lakshdeep in Marathi Language on 09th November 2025",
      "source": "BSE"
    },
    {
      "caption": "Results-Financial Results For September 30 2025",
      "datetime": "07-Nov-2025",
      "details": "Unaudited Financial Results for the quarter and half year ended 30th September 2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Anuh Pharma Ltd has declared <strong>30%</strong> dividend, ex-date: 14 Aug 25",
          "dt": "2025-08-14",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Anuh Pharma Ltd has announced <strong>5:10</strong> stock split, ex-date: 31 Jul 06",
          "dt": "2006-07-31",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Anuh Pharma Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 15 Jul 25",
          "dt": "2025-07-15",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Why is Anuh Pharma falling/rising?

2025-12-06 01:31:09

Short-Term Gains Outpace Benchmark

In the immediate term, Anuh Pharma’s stock has outperformed the broader market and its sector peers. Over the past week, the stock surged by 7.18%, significantly eclipsing the Sensex’s marginal gain of 0.01%. This recent momentum is further underscored by the stock’s intraday high of ₹83.25, representing a 5.17% increase on the day. Such performance indicates renewed investor interest and buying activity, possibly driven by short-term catalysts or market sentiment favouring the pharmaceutical sector.

Despite this positive momentum, the stock’s monthly performance remains subdued, with a decline of 5.85% compared to the Sensex’s 2.70% gain. This suggests that while recent trading sessions have been favourable, the stock has faced headw...

Anuh Pharma Faces Intense Selling Pressure Amid Prolonged Downtrend

2025-12-05 09:51:02

Anuh Pharma Ltd is currently experiencing extreme selling pressure, with the stock registering only sell orders and no buyers in the queue. This distress selling signals a challenging phase for the pharmaceutical and biotechnology company, as it continues to face a prolonged downtrend against broader market gains.

Is Anuh Pharma technically bullish or bearish?

2025-12-03 08:42:46

Technical Trend Shift and Moving Averages

As of 2 December 2025, Anuh Pharma’s technical trend has shifted from mildly bearish to outright bearish. This change reflects a deterioration in the stock’s momentum and signals increased selling pressure. The daily moving averages reinforce this view, showing a bearish alignment that typically indicates downward price movement in the near term. Moving averages are a key tool for traders to identify trend direction, and a bearish stance here suggests that the stock is struggling to maintain upward momentum.

MACD and Momentum Indicators

The Moving Average Convergence Divergence (MACD) indicator, a popular momentum oscillator, presents a mixed but predominantly negative picture. On a weekly basis, the MAC...

Anuh Pharma Technical Momentum Shifts Amid Mixed Market Signals

2025-12-03 08:07:05

Anuh Pharma, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflecting a complex interplay of bearish and mildly bullish signals across various timeframes. Recent evaluation adjustments highlight a transition in the stock’s technical trend, prompting a closer examination of its price action and indicator readings amid broader market conditions.

Anuh Pharma’s Market Assessment Shifts Amid Mixed Financial and Technical Signals

2025-12-02 08:48:13

Anuh Pharma has experienced a revision in its market evaluation following a complex interplay of financial performance, valuation metrics, and technical indicators. Despite recent quarterly setbacks and underperformance relative to broader indices, subtle shifts in technical trends and promoter activity have influenced the company’s overall market assessment.

Anuh Pharma Technical Momentum Shifts Amid Mixed Market Signals

2025-12-02 08:09:33

Anuh Pharma, a player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, reflecting a complex interplay of market forces. Recent price movements and technical indicators reveal a nuanced picture of the stock’s near-term trajectory, with mixed signals from key momentum and trend-following tools.

How has been the historical performance of Anuh Pharma?

2025-12-01 23:24:48

Revenue and Profitability Trends

Over the seven-year period ending March 2025, Anuh Pharma’s net sales have shown a robust upward trend, rising from ₹320.66 crores in 2019 to ₹661.51 crores in 2025. This represents more than a doubling of sales, reflecting the company’s expanding market presence and operational scale. The total operating income mirrors this growth, with no other operating income reported, indicating that core business activities are the primary revenue drivers.

Despite fluctuations in raw material costs and other expenses, the company has maintained a positive operating profit margin. Operating profit before other income (PBDIT excl OI) increased from ₹29.53 crores in 2019 to ₹60.90 crores in 2025, although the margin percentage saw some variability, p...

Anuh Pharma Faces Significant Selling Pressure with 27.42% Year-to-Date Loss Amid Poor Performance

2025-11-14 09:51:01

Anuh Pharma Ltd is experiencing notable selling pressure, continuing a trend of losses. The stock has declined significantly over various time frames, contrasting sharply with the Sensex's performance. Factors contributing to this trend include underperformance relative to its sector and trading below key moving averages.

How has been the historical performance of Anuh Pharma?

2025-11-12 23:21:44

Answer: The historical performance of Anuh Pharma shows a steady growth in net sales and profitability over the years, with some fluctuations in costs and margins. Breakdown: Anuh Pharma's net sales increased from 486.65 Cr in Mar'22 to 661.51 Cr in Mar'25, reflecting a consistent upward trend. Total operating income followed a similar trajectory, rising from 486.65 Cr in Mar'22 to 661.51 Cr in Mar'25. However, the raw material costs peaked at 489.73 Cr in Mar'24 before declining to 463.28 Cr in Mar'25. Operating profit (PBDIT) saw a decline from 87.24 Cr in Mar'24 to 70.36 Cr in Mar'25, while profit before tax also decreased from 78.31 Cr to 61.01 Cr in the same period. Profit after tax mirrored this trend, dropping from 60.06 Cr in Mar'24 to 47.35 Cr in Mar'25. The company's total assets grew from 347.17 Cr in Mar'22 to 504.55 Cr in Mar'25, and total liabilities increased from 347.17 Cr to 504.55 Cr duri...

View All News

Announcement

Announcement under Regulation 30 (LODR)-Investor Presentation

17-Nov-2025 | Source : BSE

Investor Presentation for Q2 FY 2025-26

Announcement under Regulation 30 (LODR)-Newspaper Publication

09-Nov-2025 | Source : BSE

Newspaper publication of the Un-Audited financial results for the Quarter and Half year ended 30th September 2025 published in the Financial Express in English Language and Mumbai Lakshdeep in Marathi Language on 09th November 2025